{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:20:18Z","timestamp":1758759618360,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.thromres.2024.01.019","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T11:30:43Z","timestamp":1707391843000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice"],"prefix":"10.1016","volume":"235","author":[{"given":"Sheng-Chieh","family":"Chou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Tzu","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Huey","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaan-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ni","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-I","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Hua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-ching","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Wha","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2024.01.019_bb0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2012.01750.x","article-title":"Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life","volume":"88","author":"Khawaji","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2024.01.019_bb0010","doi-asserted-by":"crossref","unstructured":"I. Scharrer, G.L. Bray, O. Neutzling, Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates, Haemophilia: the official journal of the World Federation of Hemophilia 5(3) (1999) 145\u201354.","DOI":"10.1046\/j.1365-2516.1999.00300.x"},{"issue":"23","key":"10.1016\/j.thromres.2024.01.019_bb0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-07-586347","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia a","volume":"124","author":"Calvez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.01.019_bb0020","doi-asserted-by":"crossref","unstructured":"C.L. Eckhardt, A.S. van Velzen, M. Peters, J. Astermark, P.P. Brons, G. Castaman, M.H. Cnossen, N. Dors, C. Escuriola-Ettingshausen, K. Hamulyak, D.P. Hart, C.R. Hay, S. Haya, W.L. van Heerde, C. Hermans, M. Holmstrom, V. Jimenez-Yuste, R.D. Keenan, R. Klamroth, B.A. Laros-van Gorkom, F.W. Leebeek, R. Liesner, A. Makipernaa, C. Male, E. Mauser-Bunschoten, M.G. Mazzucconi, S. McRae, K. Meijer, M. Mitchell, M. Morfini, M. Nijziel, J. Oldenburg, K. Peerlinck, P. Petrini, H. Platokouki, S.E. Reitter-Pfoertner, E. Santagostino, P. Schinco, F.J. Smiers, B. Siegmund, A. Tagliaferri, T.T. Yee, P.W. Kamphuisen, J.G. van der Bom, K. Fijnvandraat, I.S. Group, Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A, Blood 122(11) (2013) 1954\u201362.","DOI":"10.1182\/blood-2013-02-483263"},{"issue":"5","key":"10.1016\/j.thromres.2024.01.019_bb0025","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/rth2.12335","article-title":"Development of inhibitors in hemophilia a: an illustrated review","volume":"4","author":"Jardim","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl. 4","key":"10.1016\/j.thromres.2024.01.019_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2516.2012.02829.x","article-title":"How I treat inhibitors in haemophilia","volume":"18","author":"Makris","year":"2012","journal-title":"Haemophilia\u202f: the official journal of the World Federation of Hemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2024.01.019_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia-beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2024.01.019_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia a with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.01.019_bb0045","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in hemophilia a or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.01.019_bb0050","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel-Hett","year":"2019","journal-title":"Haemophilia: the official journal of the World Federation of Hemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.01.019_bb0055","first-page":"8","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Keiji Nogami","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.01.019_bb0060","doi-asserted-by":"crossref","unstructured":"A. Srivastava, E. Santagostino, A. Dougall, S. Kitchen, M. Sutherland, S.W. Pipe, M. Carcao, J. Mahlangu, M.V. Ragni, J. Windyga, A. Llinas, N.J. Goddard, R. Mohan, P.M. Poonnoose, B.M. Feldman, S.Z. Lewis, H.M. van den Berg, G.F. Pierce, W.F.H.G.f.t.M.o.H. panelists, a. co, WFH Guidelines for the Management of Hemophilia, 3rd edition, Haemophilia: the official journal of the World Federation of Hemophilia 26 Suppl 6 (2020) 1\u2013158.","DOI":"10.1111\/hae.14046"},{"issue":"1","key":"10.1016\/j.thromres.2024.01.019_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia a","volume":"10","author":"Bi","year":"1995","journal-title":"Nat. Genet."},{"issue":"17","key":"10.1016\/j.thromres.2024.01.019_bb0070","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/blood-2011-08-374645","article-title":"CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice","volume":"119","author":"Steinitz","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2024.01.019_bb0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nri3311","article-title":"Humanized mice for immune system investigation: progress, promise and challenges","volume":"12","author":"Shultz","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.thromres.2024.01.019_bb0080","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.thromres.2024.01.019_bb0085","doi-asserted-by":"crossref","unstructured":"F. Ishikawa, M. Yasukawa, B. Lyons, S. Yoshida, T. Miyamoto, G. Yoshimoto, T. Watanabe, K. Akashi, L.D. Shultz, M. Harada, Development of functional human blood and immune systems in NOD\/SCID\/IL2 receptor {gamma} chain(null) mice, Blood 106(5) (2005) 1565\u201373.","DOI":"10.1182\/blood-2005-02-0516"},{"issue":"10","key":"10.1016\/j.thromres.2024.01.019_bb0090","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.01.019_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12959-016-0106-0","article-title":"Current animal models of hemophilia: the state of the art","volume":"14","author":"Yen","year":"2016","journal-title":"Thromb. J."},{"issue":"9","key":"10.1016\/j.thromres.2024.01.019_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003192","article-title":"Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice","volume":"3","author":"Schmidt","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.thromres.2024.01.019_bb0105","doi-asserted-by":"crossref","first-page":"17957","DOI":"10.1038\/srep17957","article-title":"Uncovering MicroRNA regulatory hubs that modulate plasma cell differentiation","volume":"5","author":"Tsai","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.thromres.2024.01.019_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12011","article-title":"The establishment of the plasma cell survival niche in the bone marrow","volume":"251","author":"Chu","year":"2013","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.thromres.2024.01.019_bb0115","first-page":"568","article-title":"Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients","volume":"88","author":"Reding","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.01.019_bb0120","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia a patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.01.019_bb0125","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1097\/MPH.0000000000000287","article-title":"Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia a patient with high-titer factor VIII inhibitor","volume":"37","author":"Moorehead","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.thromres.2024.01.019_bb0130","article-title":"The isolation, differentiation, and quantification of human antibody-secreting B cells from blood: ELISpot as a functional readout of humoral immunity","volume":"118","author":"Tzeng","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"2","key":"10.1016\/j.thromres.2024.01.019_bb0135","first-page":"288","volume":"17","author":"Qadura","year":"2011","journal-title":"Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb\/c and C57BL\/6 haemophilia A mice, Haemophilia: the official journal of the World Federation of Hemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.01.019_bb0140","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2024.01.019_bb0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2567.2010.03263.x","article-title":"Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice","volume":"131","author":"Vandermeulen","year":"2010","journal-title":"Immunology"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2024.01.019_bb0150","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1093\/infdis\/jit319","article-title":"Overcoming current limitations in humanized mouse research","volume":"208","author":"Brehm","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.thromres.2024.01.019_bb0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","article-title":"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex","volume":"157","author":"King","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.thromres.2024.01.019_bb0160","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.thromres.2023.03.003","article-title":"The spleen is the major site for the development and expansion of inhibitor producing-cells in hemophilia a mice upon FVIII infusion developing high-titer inhibitor","volume":"231","author":"Oda","year":"2023","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2024.01.019_bb0165","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1096\/fj.201800636R","article-title":"Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression","volume":"33","author":"Brehm","year":"2019","journal-title":"FASEB J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:53:54Z","timestamp":1758736434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":33,"alternative-id":["S0049384824000252"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.01.019","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}